Ultrapar Participacoes S A : Institutional Presentation 2022 - 2Q22

2Q22 Institutional presentation

DISCLAIMER		2

• Forward-lookingstatements
• • This presentation may include forward-looking statements about future events. Such statements reflect only the expectations of the management of the Company. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Investors are cautioned that such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. For this reason, readers should not place undue emphasis on these forward-looking statements.
• Standards and criteria adopted in preparing the information
• • Ultrapar announced the signing of the sale agreements of Extrafarma and Oxiteno, according to the Material Notices disclosed on May 18, 2021 and August 16, 2021, respectively. On December 31, 2021, Ultrapar classified these businesses as assets and liabilities held for sale and discontinued operations. The sale of Oxiteno was closed on April 1st, 2022, and thus ceased to be part of discontinued operations and Ultrapar's results as of 2Q22. The sale of Extrafarma was closed on August 1st, 2022, and its results are shown within discontinued operations. In this presentation, the financial information related to Ultrapar corresponds to the consolidated information (pro forma) of the Company, that is, the data considers the sum of continuing and discontinued operations, unless otherwise indicated.
  • The financial information presented on this document were extracted from the individual and consolidated interim financial information ("Quarterly Information") for the three months period ended on June 30, 2022, and prepared in accordance with the pronouncement CPC 21 (R1) - Interim Financial Reporting and the International Accounting Standard IAS 34 - Interim Financial Reporting issued by the International Accounting Standards Board ("IASB"), and presented in accordance with the applicable rules for Quarterly Information, issued by the Brazilian Securities and Exchange Commission ("CVM"). The information related to the businesses are presented without the elimination of intersegment transactions. Therefore, the sum of such information may not correspond to Ultrapar's consolidated information (pro forma). Additionally, the financial and operational information presented in this discussion is subject to rounding and, consequently, the total amounts presented in the tables and charts may differ from the direct numerical sum of the amounts that precede them. Information denominated EBITDA are presented in accordance to Instruction No. 527, issued by CVM on October 4, 2012.

ULTRAPAR

For 85 years marked by	3
pioneering and soundness

Acquisition of

Corporate

Ipiranga

Conclusion of

Acquisition of

Streamlining the

Foundation of

Tequimar by

restructuring to

acquisition

Texaco's

Extrafarma

portfolio: divestment

Ultragaz by

Ultracargo,

own 100% of all

expands the fuel

acquisition

of Oxiteno, Extrafarma

Ernesto Igel

increasing the

businesses

distribution

and ConectCar

portfolio to the

business

logistics segment

1937

1970

1978

1999

2002

2003

2007

2008

2009

2011

2014

2017

2021

Creation of

Simultaneous

Acquisition of Shell

Acquisition of União

New corporate

Creation of Iconic,

Oxiteno and

IPO at B3 and

Gás, leading

Terminais, making

governance structure

joint venture with

beginning of the

NYSE

Ultragaz to its LPG

Ultracargo the

after joining the Novo

Chevron in lubricants

petrochemical

market leadership

largest bulk liquid

Mercado segment

operations

position

storage company

in Brazil

Ultrapar becomes a

corporation

OVERVIEW

Key figures

4

Pró forma data¹	2019	2020	2021	2Q22
(R$ million)
Net revenues	89,298	81,241	118,799	37,425	THOUSAND
15.0 EMPLOYEES
∆ YoY (%)		-9%	46%	31%
	IN JUN/22
Adjusted EBITDA	2,800	3,479	3,704	1,494
∆ YoY (%)		24%	6%	197%
Net income	403	928	884	460
Operating cash flow	2,925	3,138	2,586	376	R$ 14 BILLIONMARKET CAP
Net debt	10,269	10,537	11,691	8,172	IN JUN/22
Net debt/LTM Adjusted EBITDA²	3.0 x	3.0 x	2.9 x	2.2 x

¹ Considers the sum of continuing and discontinued operations

² LTM Adjusted EBITDA excludes Extrafarma's impairment and the capital gain from the sale of Oxiteno and ConectCar; for 2Q22 it also exludes LTM EBITDA from Oxiteno